miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir

Current Gene Therapy

Volumn 15, Issue 2, 2015, Pages 142-150

  Thakral, Sharda ^a   Ghoshal, Kalpana ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Fibrosis; Hepatitis; Hepatocellular carcinoma; Metabolism; microRNA 122; miR 122; miR 122 gene therapy; Nanoparticles mediated miR 122 delivery

Indexed keywords

ALKALINE PHOSPHATASE; AMINO ACID TRANSPORTER; ANTAGOMIR; ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; DOXORUBICIN; GAMMA GLUTAMYLTRANSFERASE; HEMOJUVELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOCKED NUCLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA 122; MICRORNA 148; MICRORNA 192; MICRORNA 194; MIRAVIRSEN; RNA 5S; SORAFENIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; MICRORNA; MIRN122 MICRORNA, HUMAN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; GENE EXPRESSION REGULATION; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; KNOCKOUT MOUSE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LUNG METASTASIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NORTHERN BLOTTING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY BILIARY CIRRHOSIS; PROTOZOAL INFECTION; REGULATORY MECHANISM; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENETICS; HEPACIVIRUS; LIVER NEOPLASMS; MOUSE; PATHOGENICITY; PATHOLOGY; PROGNOSIS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MICE; MICRORNAS; PROGNOSIS;

EID: 84965088312     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666141224095610     Document Type: Article

References (62)

1. Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liverspecific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1(2):106-13.
2. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002;12(9):735-9.
3. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129(7):1401-14.
4. Wienholds E, Kloosterman WP, Miska E, et al. MicroRNA expression in zebrafish embryonic development. Science 2005;309(5732):310-1.
5. Filipowicz W, Grosshans H. The liver-specific microRNA miR-122: biology and therapeutic potential. Prog Drug Res 2011;67:221-38.
6. Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012;9(2):137-42.
7. Hsu SH, Ghoshal K. MicroRNAs in Liver Health and Disease. Curr Pathobiol Rep 2013;1(1):53-62.
8. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013;10(9):542-52.
9. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009;28(40):3526-36.
10. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50(2):136-42.
11. Ward J, Kanchagar C, Veksler-Lublinsky I, et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci U S A 2014; 111(33):12169-74.
12. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013;58(2):777-87.
13. Jopling CL. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans 2008;36(Pt 6):1220-3.
14. Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell 2012;3(5):364-71.
15. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368(18):1685-94.
16. Hsu SH, Wang B, Kota J, et al. Essential metabolic, antiinflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012;122(8):2871-83.
17. Tsai WC, Hsu SD, Hsu CS, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122(8):2884-97.
18. Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009;284(46):32015-27.
19. Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009;49(5):1571-82.
20. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008;48(6):1810-20.
21. Takaki Y, Saito Y, Takasugi A, et al. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from nonalcoholic steatohepatitis. Cancer Sci 2014; 105(10):1254-60.
22. Gatfield D, Le Martelot G, Vejnar CE, et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev 2009;23(11):1313-26.
23. Xu H, He JH, Xiao ZD, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010;52(4):1431-42.
24. Laudadio I, Manfroid I, Achouri Y, et al. A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation. Gastroenterology 2012;142(1):119-29.
25. D’Ambrogio A, Gu W, Udagawa T, Mello CC, Richter JD. Specific miRNA stabilization by Gld2-catalyzed monoadenylation. Cell Rep 2012;2(6):1537-45.
26. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ’antagomirs’. Nature 2005;438(7068):685-9.
27. Davoodian N, Lotfi AS, Soleimani M, Mowla SJ. MicroRNA-122 overexpression promotes hepatic differentiation of human adipose tissue-derived stem cells. J Cell Biochem 2014;115(9):1582-93.
28. Deng XG, Qiu RL, Wu YH, et al. Overexpression of miR-122 promotes the hepatic differentiation and maturation of mouse ESCs through a miR-122/FoxA1/HNF4a-positive feedback loop. Liver Int 2014;34(2):281-95.
29. Doddapaneni R, Chawla YK, Das A, Kalra JK, Ghosh S, Chakraborti A. Overexpression of microRNA-122 enhances in vitro hepatic differentiation of fetal liver-derived stem/progenitor cells. J Cell Biochem 2013;114(7):1575-83.
30. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006;125(6):1111-24.
31. Kojima S, Gatfield D, Esau CC, Green CB. MicroRNA-122 modulates the rhythmic expression profile of the circadian deadenylase Nocturnin in mouse liver. PLoS One 2010;5(6):e11264.
32. Castoldi M, Vujic Spasic M, Altamura S, et al. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 2011;121(4):1386-96.
33. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3(2):87-98.
34. Hsu SH, Wang B, Kutay H, et al. Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure. Am J Pathol 2013;183(6):1719-30.
35. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452(7189):896-9.
36. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8(1):35-44.
37. Padgett KA, Lan RY, Leung PC, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009;32(3-4):246-53.
38. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006;99(3):671-8.
39. Wang X, Yu B, Ren W, et al. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. J Control Release 2013;172(3):690-8.
40. Wang B, Majumder S, Nuovo G, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009;50(4):1152-61.
41. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436(7053):953-60.
42. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005;309(5740):1577-81.
43. Wang S, Qiu L, Yan X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity. Hepatology 2012;55(3):730-41.
44. Chen Y, Shen A, Rider PJ, et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011;25(12):4511-21.
45. Fan CG, Wang CM, Tian C, et al. miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol Rep 2011;26(5):1281-6.
46. Ghosh J, Bose M, Roy S, Bhattacharyya SN. Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. Cell Host Microbe 2013;13(3):277-88.
47. Gambari R, Fabbri E, Borgatti M, et al. Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem Pharmacol 2011;82(10):1416-29.
48. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011;18(12):1104-10.
49. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 2014;13(8):622-38.
50. Fornari F, Gramantieri L, Giovannini C, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009;69(14):5761-7.
51. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008;283(44):29897-903.
52. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genetics 2011;12(5):341-55.
53. Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137(6):1005-17.
54. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365(25):2357-65.
55. Hsu SH, Yu B, Wang X, et al. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine 2013;9(8):1169-80.
56. Lo A, Lin CT, Wu HC. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 2008;7(3):579-89.
57. Zhang M, Zhou X, Wang B, et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release 2013;168(3):251-61.
58. Xie J, Ameres SL, Friedline R, et al. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods 2012;9(4):403-9.
59. Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011;43(4):371-8.
60. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327(5962):198-201.
61. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75(5):843-54.
62. Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genetics 2014;15(7):445-51.